Munir Muhammad Muaaz, Rasheed Huma, Khokhar Muhammad Imran, Khan Rizwan Rasul, Saeed Hafiz Asad, Abbas Mateen, Ali Mohsin, Bilal Rabiea, Nawaz Hafiz Awais, Khan Abdul Muqeet, Qamar Shaista, Anjum Syed Muneeb, Usman Muhammad
Institute of Pharmaceutical Sciences, University of Veterinary and Animal Sciences, Lahore, Pakistan.
Ameer-ud-Din Medical College, Post-Graduate Medical Institute (PGMI), Lahore General Hospital, Lahore, Pakistan.
Front Pharmacol. 2021 Nov 11;12:721819. doi: 10.3389/fphar.2021.721819. eCollection 2021.
Vancomycin is a narrow therapeutic agent, and it is necessary to optimize the dose to achieve safe therapeutic outcomes. The purpose of this study was to identify the significant covariates for vancomycin clearance and to optimize the dose among surgical patients in Pakistan. Plasma concentration data of 176 samples collected from 58 surgical patients treated with vancomycin were used in this study. A population pharmacokinetic model was developed on NONMEM using plasma concentration-time data. The effect of all available covariates was evaluated on the pharmacokinetic parameters of vancomycin by stepwise covariate modeling. The final model was evaluated using bootstrap, goodness-of-fit plots, and visual predictive checks. The pharmacokinetics of vancomycin followed a one-compartment model with first-order elimination. The vancomycin clearance (CL) and volume of distribution (Vd) were 2.45 L/h and 22.6 l, respectively. Vancomycin CL was influenced by creatinine clearance (CRCL) and body weight of the patients; however, no covariate was significant for its effect on the volume of distribution. Dose tailoring was performed by simulating dosage regimens at a steady state based on the CRCL of the patients. The tailored doses were 400, 600, 800, and 1,000 mg for patients with a CRCL of 20, 60, 100, and 140 ml/min, respectively. Vancomycin CL is influenced by CRCL and body weight of the patient. This model can be helpful for the dose tailoring of vancomycin based on renal status in Pakistani patients.
万古霉素是一种治疗窗较窄的药物,因此有必要优化剂量以实现安全的治疗效果。本研究的目的是确定影响万古霉素清除率的显著协变量,并为巴基斯坦外科患者优化剂量。本研究使用了从58例接受万古霉素治疗的外科患者中收集的176份样本的血浆浓度数据。利用血浆浓度-时间数据在NONMEM上建立了群体药代动力学模型。通过逐步协变量建模评估所有可用协变量对万古霉素药代动力学参数的影响。使用自抽样法、拟合优度图和可视化预测检验对最终模型进行评估。万古霉素的药代动力学遵循具有一级消除的单室模型。万古霉素的清除率(CL)和分布容积(Vd)分别为2.45 L/h和22.6 L。万古霉素CL受患者肌酐清除率(CRCL)和体重的影响;然而,没有协变量对其分布容积有显著影响。根据患者的CRCL模拟稳态给药方案进行剂量调整。CRCL分别为20、60、100和140 ml/min的患者的调整剂量分别为400、600、800和1000 mg。万古霉素CL受患者CRCL和体重的影响。该模型有助于根据巴基斯坦患者的肾脏状况对万古霉素进行剂量调整。